BCL2 and B-cell chronic lymphocytic leukemia: BCL-2-selective inhibitor venetoclax (ABT-199) has demonstrated clinical activity in chronic lymphocytic leukemia (CLL) and has recently received FDA-approval for some relapsed CLL patients [1].